Kineta, Inc.
Performance History
| Key Stats | |
|---|---|
| Open | $3.47 |
| Prev. Close | $3.28 |
| EPS | -10.54 |
| Dividend | $0.00 |
| Next Earnings Date | Aug 11, 2023 |
| Dividend Yield % | 276.52% |
| Market Cap | $36.37M |
| PE Ratio | - |
| low | high | |
|---|---|---|
| Day Range | 3.43 | 3.59 |
| 52 Week Range | 1.78 | 15.54 |
| Ratios | |
|---|---|
| P/B Ratio | 12.56 |
| Revenue | $5.92M |
| Operating M. % | -330.61% |
| Earnings | -$58.34M |
| Earnings Growth % | -100.00% |
| EBITDA Margin % | -329.95% |
| ROE % | 0.00% |
| EPS | -10.54 |
Score Breakdown
All Score (51 / 100) is to help users identify stocks that trade at a low value relative to their fundamentals. Suitable for value investors such as Warren Buffet.
| KA | Market | |
|---|---|---|
| Value | 66 | 42 |
| Quality | 42 | 46 |
| Ownership | 20 | 39 |
| Growth | 45 | 44 |
| Dividends | 33 | 32 |
All Score (51 / 100) is to help users identify stocks that trade at a low value relative to their fundamentals. Suitable for value investors such as Warren Buffet.
Financial Forecast
AI Price Prediction
Analyst Ratings
Correlated Companies
About Kineta, Inc. (KA)
Kineta, Inc., a clinical-stage biotechnology company, develops immunotherapies in the field of immuno-oncology, cancer, neurology, and arenaviruses. The company is developing KVA12123, an anti-VISTA antagonist mAb immunotherapy, which is in Phase 1/2 clinical trials for the treatment of solid tumors, including non-small cell lung cancer, ovarian cancer, colorectal cancer, colon cancer, pancreatic cancer, and gastric cancer. It is also developing anti-CD27 agonist mAb immunotherapy, which is in Phase 1 clinical trials for the treatment of advanced solid tumors, such as renal cell carcinoma, ovarian cancer, and colorectal cancer. In addition, the company develops immunotherapies for pain management and anti-viral therapy for the treatment of emerging diseases. Kineta, Inc. has collaboration and license agreements with MSD International Business GmbH, and GigaGen, Inc. The company was formerly known as Lecura, Inc. Kineta, Inc. was founded in 2007 and is headquartered in Seattle, Washington.
- ISN
- -
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Dr. Shawn P. Iadonato Ph.D.
- Headquarters
- Seattle
- Employees
- 11
Keep an eye on Kineta, Inc.
Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.
News
Sign up for our newsletter
Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.